Current Development Status of MEK Inhibitors
AbstractThe current development status of mitogen-activated protein kinase kinase (MEK) inhibitors, including the preclinical data and clinical study progress, has been summarized in this review. Different MEK inhibitors, possessing specific physicochemical properties and bioactivity characteristics, may provide different options for patients seeking treatment for cancer. Moreover, the combination of the MEK inhibitors with other therapies—such as chemotherapy, targeted therapy, and immunotherapy—may be a promising approach for clinical use. View Full-Text
Share & Cite This Article
Cheng, Y.; Tian, H. Current Development Status of MEK Inhibitors. Molecules 2017, 22, 1551.
Cheng Y, Tian H. Current Development Status of MEK Inhibitors. Molecules. 2017; 22(10):1551.Chicago/Turabian Style
Cheng, Ying; Tian, Hongqi. 2017. "Current Development Status of MEK Inhibitors." Molecules 22, no. 10: 1551.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.